The MCO market is undergoing unprecedented consolidation with far-reaching effects for the Life Sciences industry.

  • It may very well be that the health plan industry is shifting away from contracting with stand-alone PBMs back to MCOs controlling their own pharmacy management.
  • Many impacts on Medicare Part D market, Medicaid market, Medicare Advantage Market, geographies, public healthcare exchanges, benefit design, and alternative contracting models.

Impact of COVID-19 on the development of CAR T-cell therapies

View Now